Issue 13, 2025

In situ self-assembled peptide nanoparticles improve the anti-hepatic fibrosis effect

Abstract

Antagonistic peptide Leu-Ser-Lys-Leu (LSKL) is capable of blocking the transforming growth factor-β1 (TGF-β1) signaling pathway and exhibits anti-fibrotic effects. Herein, we constructed LSKL nanoparticles (NPs) in situ based on an alkaline phosphatase (ALP)-instructed self-assembly strategy for improving its specific therapeutic effect against liver fibrosis.

Graphical abstract: In situ self-assembled peptide nanoparticles improve the anti-hepatic fibrosis effect

Supplementary files

Article information

Article type
Communication
Submitted
20 Dec 2024
Accepted
05 Mar 2025
First published
07 Mar 2025

J. Mater. Chem. B, 2025,13, 4080-4084

In situ self-assembled peptide nanoparticles improve the anti-hepatic fibrosis effect

W. Liu, B. Wang, M. Wei and Z. Hai, J. Mater. Chem. B, 2025, 13, 4080 DOI: 10.1039/D4TB02819H

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements